High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2023 Jul 31

PMID 37523146

Authors

Chelsea Mayoh

Jie Mao

Jinhan Xie

Gabor Tax

Shu-Oi Chow

Roxanne Cadiz

Karina Pazaky

Paulette Barahona

Pamela Ajuyah

Peter Trebilcock

Angela Malquori

Kate Gunther

Anica Avila

Doo Young Yun

Stephanie Alfred

Anjana Gopalakrishnan

Alvin Kamili

Marie Wong

Mark J Cowley

Sophie Jessop

Loretta M S Lau

Toby N Trahair

David S Ziegler

Jamie I Fletcher

Andrew J Gifford

Maria Tsoli

Glenn M Marshall

Michelle Haber

Vanessa Tyrrell

Timothy W Failes

Greg M Arndt

Richard B Lock

Paul G Ekert

M Emmy M Dolman

Affiliations

Soon will be listed here.

Abstract

Significance: Integrating HTS with molecular profiling is a powerful tool for expanding precision medicine to support drug treatment recommendations and broaden the therapeutic options available to high-risk pediatric cancers.

Citing Articles

Tumor organoids in cancer medicine: from model systems to natural compound screening.

Cong R, Lu C, Li X, Xu Z, Wang Y, Sun S Pharm Biol. 2025; 63(1):89-109.

PMID: 39893515 PMC: 11789228. DOI: 10.1080/13880209.2025.2458149.

Bridging the gap: From petri dish to patient - Advancements in translational drug discovery.

El-Tanani M, Rabbani S, El-Tanani Y, Matalka I, Khalil I Heliyon. 2025; 11(1):e41317.

PMID: 39811269 PMC: 11730937. DOI: 10.1016/j.heliyon.2024.e41317.

Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.

Rouaen J, Salerno A, Shai-Hee T, Murray J, Castrogiovanni G, McHenry C Nat Commun. 2024; 15(1):10462.

PMID: 39668192 PMC: 11638255. DOI: 10.1038/s41467-024-54689-x.

Establishment and Clinical Significance of the Patient-Derived Xenograft Model of Colorectal Cancer.

Zhang L, Li Y, Yao L, He R, Wu J Cureus. 2024; 16(10):e71116.

PMID: 39525113 PMC: 11544153. DOI: 10.7759/cureus.71116.

Molecular and modular intricacies of precision oncology.

Chhabra R Front Immunol. 2024; 15:1476494.

PMID: 39507541 PMC: 11537923. DOI: 10.3389/fimmu.2024.1476494.

References

Luserna di Rora A, Cerchione C, Martinelli G, Simonetti G . A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020; 13(1):126. PMC: 7507691. DOI: 10.1186/s13045-020-00959-2. View

Sadasivam S, DeCaprio J . The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013; 13(8):585-95. PMC: 3986830. DOI: 10.1038/nrc3556. View

Lee J, Liu Z, Sa J, Shin S, Wang J, Bordyuh M . Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nat Genet. 2018; 50(10):1399-1411. PMC: 8514738. DOI: 10.1038/s41588-018-0209-6. View

Slade D . PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020; 34(5-6):360-394. PMC: 7050487. DOI: 10.1101/gad.334516.119. View

Dagogo-Jack I, Shaw A . Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2017; 15(2):81-94. DOI: 10.1038/nrclinonc.2017.166. View

Harris M, Dubois S, Glade Bender J, Kim A, Crompton B, Parker E . Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016; 2(5):608-615. DOI: 10.1001/jamaoncol.2015.5689. View

Harttrampf A, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N . Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017; 23(20):6101-6112. DOI: 10.1158/1078-0432.CCR-17-0381. View

Wong M, Mayoh C, Lau L, Khuong-Quang D, Pinese M, Kumar A . Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020; 26(11):1742-1753. DOI: 10.1038/s41591-020-1072-4. View

Parsons D, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K . Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. JAMA Oncol. 2016; 2(5):616-624. PMC: 5471125. DOI: 10.1001/jamaoncol.2015.5699. View

10.

Sun H, Cao S, Mashl R, Mo C, Zaccaria S, Wendl M . Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun. 2021; 12(1):5086. PMC: 8384880. DOI: 10.1038/s41467-021-25177-3. View

11.

Hong D, Dubois S, Kummar S, Farago A, Albert C, Rohrberg K . Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020; 21(4):531-540. PMC: 7497841. DOI: 10.1016/S1470-2045(19)30856-3. View

12.

Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K . Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018; 359(6378):920-926. PMC: 6112415. DOI: 10.1126/science.aao2774. View

13.

Pilie P, Gay C, Byers L, OConnor M, Yap T . PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. Clin Cancer Res. 2019; 25(13):3759-3771. DOI: 10.1158/1078-0432.CCR-18-0968. View

14.

Ghandi M, Huang F, Jane-Valbuena J, Kryukov G, Lo C, McDonald 3rd E . Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019; 569(7757):503-508. PMC: 6697103. DOI: 10.1038/s41586-019-1186-3. View

15.

Nicolaides T, Nazemi K, Crawford J, Kilburn L, Minturn J, Gajjar A . Phase I study of vemurafenib in children with recurrent or progressive BRAF mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget. 2020; 11(21):1942-1952. PMC: 7260122. DOI: 10.18632/oncotarget.27600. View

16.

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

17.

Izquierdo E, Carvalho D, Mackay A, Temelso S, Boult J, Pericoli G . DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. Cancer Discov. 2021; 12(3):712-729. PMC: 7612484. DOI: 10.1158/2159-8290.CD-20-0930. View

18.

Fouladi M, Laningham F, Wu J, OShaughnessy M, Molina K, Broniscer A . Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol. 2007; 25(30):4806-12. DOI: 10.1200/JCO.2007.11.4017. View

19.

van Tilburg C, Pfaff E, Pajtler K, Langenberg K, Fiesel P, Jones B . The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. Cancer Discov. 2021; 11(11):2764-2779. PMC: 9414287. DOI: 10.1158/2159-8290.CD-21-0094. View

20.

Sabir S, Yeoh S, Jackson G, Bayliss R . EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. Cancers (Basel). 2017; 9(9). PMC: 5615333. DOI: 10.3390/cancers9090118. View